Bladder Cancer

>

Latest News

Sacituzumab Govitecan Yields ‘Limited Efficacy’ in Previously Treated Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Yields ‘Limited Efficacy’ in Previously Treated Metastatic Urothelial Carcinoma

June 10th 2024

Patients treated with enfortumab vedotin before sacituzumab govitecan had low objective response rates and median PFS, which may raise questions about this sequencing approach.

Nadofaragene Firadenovec Shows 5-Year Anti-Tumor Activity in NMIBC
Nadofaragene Firadenovec Shows 5-Year Anti-Tumor Activity in NMIBC

May 27th 2024

TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer

May 9th 2024

UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset

May 8th 2024

Nadofaragene Firadenovec Produces Sustained, Durable Responses in NMIBC
Nadofaragene Firadenovec Produces Sustained, Durable Responses in NMIBC

May 5th 2024

Video Series
Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.